Literature DB >> 11869610

Antibiotics for trachoma.

D Mabey1, N Fraser-Hurt.   

Abstract

BACKGROUND: Trachoma is the world's leading cause of preventable blindness. In 1997 the World Health Organization launched an initiative on trachoma control based on the 'SAFE' strategy (surgery, antibiotics, facial cleanliness and environmental improvement).
OBJECTIVES: The aim of this review is to assess the evidence supporting the antibiotic arm of the SAFE strategy by assessing the effects of antibiotics on both active trachoma (primary objective) and on Chlamydia trachomatis infection of the conjunctiva (secondary objective). SEARCH STRATEGY: We searched The Cochrane Controlled Trials Register - CENTRAL/CCTR, which contains the Cochrane Eyes and Vision Group specialised register (Cochrane Library Issue 3, 2001), MEDLINE (1966 to August 2001), and EMBASE (1980 to September 2001). We used the Science Citation Index to look for articles that cited the included studies. We searched the reference lists of identified articles and we contacted authors and experts for details of further relevant studies. SELECTION CRITERIA: We included only randomised trials that satisfied either of two criteria: (a) trials in which topical or oral administration of an antibiotic was compared to placebo or no treatment in people with trachoma, (b) trials in which a topical antibiotic was compared with an oral antibiotic in people with trachoma. A subdivision of particular interest was of trials in which topical tetracycline/chlortetracycline was compared with oral azithromycin, as these are the two World Health Organization recommended treatments. DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed trial quality and extracted data. We contacted investigators for missing data. MAIN
RESULTS: We found 15 studies that randomised a total of 8678 participants. For both outcomes (active trachoma and laboratory evidence of infection) the results of the chi-square tests suggested that there was significant statistical heterogeneity among the trials. There was also marked clinical heterogeneity. No summary statistics were calculated and we therefore present a narrative summary of the results. For the comparisons of oral or topical antibiotic against placebo/no treatment, the data are consistent with there being no effect of antibiotics but are suggestive of a lowering of the point prevalence of relative risk of both active disease and laboratory evidence of infection at three and 12 months after treatment. For the comparison of oral against topical antibiotics the results suggest that oral treatment is neither more nor less effective than topical treatment. REVIEWER'S
CONCLUSIONS: There is some evidence that antibiotics reduce active trachoma but results are not consistent and cannot be pooled.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11869610     DOI: 10.1002/14651858.CD001860

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  5 in total

1.  Trachoma, antibiotics and randomised controlled trials.

Authors:  B Shapiro; K Dickersin; T Lietman
Journal:  Br J Ophthalmol       Date:  2006-12       Impact factor: 4.638

2.  Distance to water source and altitude in relation to active trachoma in Rombo district, Tanzania.

Authors:  R F Baggaley; A W Solomon; H Kuper; S Polack; P A Massae; J Kelly; S Safari; N D E Alexander; P Courtright; A Foster; D C Mabey
Journal:  Trop Med Int Health       Date:  2006-02       Impact factor: 2.622

3.  Antibiotics for trachoma.

Authors:  Jennifer R Evans; Anthony W Solomon; Rahul Kumar; Ángela Perez; Balendra P Singh; Rajat Mohan Srivastava; Emma Harding-Esch
Journal:  Cochrane Database Syst Rev       Date:  2019-09-26

4.  Cochrane systematic reviews and co-publication: dissemination of evidence on interventions for ophthalmic conditions.

Authors:  Xue Wang; Barbara S Hawkins; Kay Dickersin
Journal:  Syst Rev       Date:  2015-09-22

5.  Status of active trachoma infection among school children who live in villages of open field defecation: a comparative cross-sectional study.

Authors:  Demoze Delelegn; Alemu Tolcha; Hunachew Beyene; Berhan Tsegaye
Journal:  BMC Public Health       Date:  2021-11-09       Impact factor: 4.135

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.